Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07241936 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started2025-11-13
View on ClinicalTrials.gov ↗

Amendment history

2025-11-21
Study Status, Study Design v1
Re-verified, no change to tracked fields
2025-11-17
Original filing
This study adopts a multi-center, open-label, non-randomized trial design. It plans to enroll patients with Advanced solid tumor. Dose-escalation and PK-expansion studies will be carried out to evaluate the safety, tolerability, and preliminary efficacy of sirolimus (albumin-bound) in combination with Different ADCs (DP303c/SYS6043/SYS6002/SYS6010) in this patient population, and to confirm the recommended phase 2 dose (RP2D).
Trial Details
NCT Number NCT07241936
Lead Sponsor CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 444 participants
Start Date 2025-11-13
Primary Completion 2027-10-30 (estimated)
Study Completion 2028-10-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-28